Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

Chronic Obstructive Pulmonary Disease COPD Concept. IvelinRadkov. Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent …

Share on Facebook

Tweet

Follow us

Save